SGLT2-inhibition and Vascular Euphoria a Reconciliation of Vascular Health and Disease Homeostasis.
| Autor: | Tiwaskar M; Consultant Physician & Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra., Kalra S; Consultant Endocrinologist, Bharti Hospital, Haryana., Bantwal G; Professor and Head of the Department of Endocrinology, St. Johns Medical College & Hospital, Bengaluru, Karnataka., Bhattacharya A; Consultant Endocrinologist, Manipal Hospital, Bengaluru, Karnataka., Sahay M; Professor and Head of Nephrology Department, Osmania General Hospital, Hyderabad, Telangana., Jadhav U; Consultant Cardiologist, MGM Hospital, Navi Mumbai, Maharashtra., Joshi A; Consultant Endocrinologist, Bhaktivedanta Hospital and Research Institute, Mumbai, Maharashtra., Das AK; Professor and Head of Endocrinology, Pondicherry Institute of Medical Sciences, Puducherry., Khullar D; Chairman - Nephrology and Renal Transplant Medicine, Department of Nephrology and Renal transplant medicine, Max Super Speciality Hospital, New Delhi., Baruah M; Consultant Endocrinologist, Excel care Hospitals, Guwahati, Assam., Punyani H; Consultant Diabetologist, Apollo Cradle Hospital, New Delhi., Kishor K; Consultant Cardiologist, RAMA Superspeciality and Critical Care Hospital, Karnal, Haryana., Shetty K; Department of Medical Affairs, Boehringer Ingelheim., Ved J; Department of Medical Affairs, Boehringer Ingelheim. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of the Association of Physicians of India [J Assoc Physicians India] 2021 Apr; Vol. 69 (4), pp. 11-12. |
| Abstrakt: | The concept of SGLT2-inhibition, once regarded as a non-physiological approach to glycemia control, now finds a foundational relevance in risk-modification for cardiovascular, kidney, and metabolic outcomes, spanning beyond type-2 diabetes. Major studies have proven meaningful improvements in various clinical outcomes, with different SGLT2-i agents. Apart from glycosuria, SGLT2-inhibition is associated with several patho-physiological effects, which may contribute to the clinical benefits seen with these agents. This narrative review is an attempt to appraise the different patho-physiological effects mediated by SGLT2-inhibition, based on contemporary evidence. The review classifies these effects in the acronym of EUPHORIA, and grades the possible relevance of each effect, in improving clinical outcomes. (© Journal of the Association of Physicians of India 2011.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|